NBIX vs OPAL · P/E 45, rev $2.36B vs P/E 26, rev $349.0M
Neurocrine Biosciences Inc (NBIX) versus OPAL Fuels Inc (OPAL) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
OPAL Fuels Inc (OPAL) is a utilities - regulated gas company listed on NASDAQ.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported OPAL revenue for 2025-12-31 was $349.0M. Net income was $36.4M. Revenue was up 16.3% from 2024-12-31 to 2025-12-31. OPAL currently screens at market cap $318.1M and trailing P/E 26.0.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. OPAL currently screens at market cap $318.1M and trailing P/E 26.0.
Not investment advice. Open the NBIX and OPAL stock pages for the full models.
Not investment advice.